Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 13, 2026
TickeronGET DAILY SIGNALS
Artiva Biotherapeutics (ARTV) Declines -33% Over 30 Days After Halting Lead Program

Artiva Biotherapeutics (ARTV) Declines -33% Over 30 Days After Halting Lead Program

Key Takeaways

  • Artiva Biotherapeutics (ARTV) shares fell roughly 33% over the past 30 days, moving from near $5.91 down to around $3.95.
  • The drop followed the company's decision to stop development of AlloNK (AB-101), its primary natural killer cell therapy candidate.
  • Artiva pointed to insufficient durability of response and two Grade 5 safety events as reasons for ending the program.
  • The firm announced an approximately 94% workforce reduction and is now reviewing strategic options such as a merger, asset sale, or liquidation.
  • Shares plunged 30.68% in one session on October 27, 2026, closing at $4.27 before drifting lower.
  • Over the last three months, the stock has lost roughly 65% from about $11.30 in mid-August.

Artiva Biotherapeutics (ARTV) and Its Clinical Focus

Artiva Biotherapeutics, Inc. is a clinical-stage biotech firm based in San Diego that develops allogeneic, off-the-shelf natural killer cell therapies aimed at autoimmune diseases. Its lead candidate, AlloNK (AB-101), was a non-genetically modified, cryopreserved NK cell therapy intended to boost the antibody-dependent cellular cytotoxicity of anti-CD20 antibodies and achieve deep B-cell depletion. The company had been advancing AlloNK combined with rituximab in indications including rheumatoid arthritis, Sjögren disease, systemic sclerosis, and myositis. ARTV listed on the Nasdaq Global Market in July 2024 and, before the October 2026 update, had been preparing to start a Phase 3 trial in refractory RA.

ARTV Stock Performance Over the Past 30 Days and Quarter

Over the last 30 days, ARTV declined about 33%, moving from a closing price near $5.91 in mid-October to roughly $3.95. Most of the move occurred on October 27, 2026, when the stock fell 30.68% to close at $4.27 after the company disclosed it would halt AlloNK development. Shares continued to ease lower in the following weeks as the clinical program wound down and the strategic review progressed. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The three-month view shows an even steeper decline. In mid-August, ARTV traded around $11.30 on the back of early Phase 2a data and raised analyst targets. Over the next three months the stock lost roughly 65% of its value as clinical setbacks mounted and ultimately led to the discontinuation of the sole lead program.

What Triggered the Recent Selloff

The key event was the October 27, 2026 announcement that Artiva would discontinue further work on AlloNK. While updated data still showed deep B-cell depletion and clinical activity in line with earlier results, longer-term follow-up fell short of the durability needed to justify continued development. The decision was also influenced by two Grade 5 safety events: one case of leukoencephalopathy likely linked to fludarabine-associated neurotoxicity and a second sudden-death event deemed unrelated to treatment.

Along with the halt, Artiva disclosed a roughly 94% workforce reduction and stated it is evaluating strategic alternatives to maximize stockholder value, which could include a merger, business combination, asset sale or licensing, or dissolution and liquidation. The company retained Leerink Partners as financial advisor and reported approximately $319.1 million in cash, cash equivalents, and investments as of September 30, 2026. The single-day 30.68% drop reflected the market’s reassessment once the lead asset was removed.

Quarterly Drivers and the Shift in Sentiment

The broader three-month decline marks a sharp reversal. As recently as August 2026, Artiva had reported encouraging early data in difficult-to-treat RA patients, received FDA RMAT designation for AlloNK plus rituximab in refractory RA, and completed an approximately $300 million offering in May 2026 to support Phase 3 plans. Sell-side analysts had raised price targets on the strength of those results.

Optimism faded through September and October as safety concerns surfaced and the FDA requested a pause in enrollment and dosing in the Phase 2a basket trial. The downward move accelerated into the late-October decision to stop development entirely, removing much of the value previously attached to AlloNK’s clinical and commercial potential.

What to Watch Next for ARTV

Going forward, the main variable remains the outcome of the strategic-alternatives process. Investors will track whether the board pursues a merger, business combination, asset sale or licensing deal, or instead moves toward dissolution and liquidation. The company’s final cash position and wind-down costs—estimated at roughly $10 million to $15 million for contract terminations and $17 million to $20 million in severance-related expenses—will also draw attention.

Other items include any resolution of litigation or regulatory inquiries, such as the shareholder investigation announced in November 2026, plus updates on remaining assets. Because Artiva has indicated it does not plan to provide further updates unless the board approves a specific path, periods of limited disclosure could continue. These factors carry substantial uncertainty, and no particular outcome is assured.

Using AI Tools for Market Context

When reviewing fast-moving biotech names like this, I often consult Tickeron’s AI Trading Bots to compare automated strategies across similar tickers and timeframes. The platform lets users filter bots by performance metrics and risk parameters, which helps place individual stock moves in a broader, data-driven context without replacing fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARTV

ARTV's RSI Oscillator is sitting in oversold zone for 13 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for ARTV just turned positive on November 09, 2026. Looking at past instances where ARTV's MACD turned positive, the stock continued to rise in 20 of 21 cases over the following month. The odds of a continued upward trend are 90%.

Following a +2.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARTV advanced for three days, in 95 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

ARTV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARTV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for ARTV entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.584) is normal, around the industry mean (3.498). P/E Ratio (-1.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (81.301) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ARTV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
5505 Morehouse Drive
Phone
+1 858 267-4467
Employees
104
Web
https://www.artivabio.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.